NCT06243770View on ClinicalTrials.gov

Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

June 12, 2025

Study Completion Date

June 12, 2025

Conditions

Healthy Participants

Interventions

DRUG

mRNA-0184

Intravenous infusion

Trial Locations (1)

3004

Nucleus Network, Melbourne

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY